Objective: This study was to specifically silence the minichromosome maintenance protein 7 (MCM7) expressions with lentivirus-mediated RNA interference technique in liver cancer MHCC-97H cells and its biological consequences were investigated.
Methods: Human MCM7 sequence was used for the design of shRNA targeting MCM7 which was then introduced to lentivirus, followed by transfection into MHCC-97H cells. Real time quantitative PCR and Western blot assay were performed to detect the mRNA and protein expression of MCM7 in these cells. MTT assay was performed to detect cell proliferation, flow cytometry to detect cell cycle and apoptosis, scratch-wound assay to detect cell migration ability, and transwell invasion assay to evaluate the invasion of these cells.
Results: We successfully constructed LV-mcm7-RNAi expressing MCM7 shRNA. PCR and Western blot assay showed the mRNA and protein expression of MCM7 reduced significantly when compared with negative control group (LV-NC-RNAi) and blank control group (P<0.05). As compared to blank control group and negative control group, the cell proliferation reduced dramatically (P<0.01), cells were mainly arrested in G0/G1 phase and apoptotic cells increased markedly in LV-mcm7-RNAi group. Moreover, cells transfected with LV-mcm7-RNAi showed significant reductions in the invasion and migration as compared to other groups (P<0.05).
Conclusion: Lentivirus mediated silencing of MCM7 with shRNA in MHCC-97H cells may inhibit the malignant behaviors of MHCC-97H cells (suppressed proliferation and compromised invasiveness), which is related to the cell cycle arrest and increase in apoptosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538142 | PMC |
Anticancer Agents Med Chem
January 2025
Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, 510220, Guangzhou, China.
Background: Hepatocellular Carcinoma (HCC) is a highly prevalent cancer worldwide, necessitating effective treatment options. However, current treatments do not provide satisfactory results. Quinacrine, a synthetic drug belonging to the 9-aminoacridine family, has demonstrated promising antitumor effects.
View Article and Find Full Text PDFMol Med Rep
March 2025
The First Central Clinical School, Tianjin Medical University, Tianjin 300000, P.R. China.
Hepatocellular carcinoma (HCC) is a common cause of cancer‑related mortality and morbidity worldwide. While iodine‑125 (I) particle brachytherapy has been extensively used in the clinical treatment of various types of cancer, the precise mechanism underlying its effectiveness in treating HCC remains unclear. In the present study, MHCC‑97H cells were treated with I, after which, cell viability and proliferation were assessed using Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine and colony formation assays, cell invasion and migration were evaluated using wound healing and Transwell assays, and cell apoptosis was determined using flow cytometry.
View Article and Find Full Text PDFAsian J Surg
July 2024
Department of Radiology, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China. Electronic address:
Background: Recent studies show that ribosomal protein S21 (RPS21) plays a role in the development and progression of various malignancies. However, the biological value of RPS21 in hepatocellular carcinoma (HCC) and its association with immunotherapy remain unknown.
Methods: Here, we examined the differential expression of RPS21 between HCC and normal liver tissues, using the TCGA, ICGC and GEO databases, followed by verification by reverse-transcription quantitative polymerase chain reaction (RT-qPCR) in LO2, SMMC7721, HepG2, and MHCC-97H cell lines.
Transl Oncol
September 2024
Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong 250117, China; State Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, 22 Hankou Road, Nanjing, Jiangsu, 210093 China; Department of Hepatobiliary Surgery, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China. Electronic address:
Background And Purpose: Regorafenib was approved by the US Food and Drug Administration (FDA) for hepatocellular carcinoma (HCC) patients showing progress on sorafenib treatment. However, there is an inevitably high rate of drug resistance associated with regorafenib, which reduces its effectiveness in clinical treatment. Thus, there is an urgent need to find a potential way to solve the problem of regorafenib resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!